American Journal of Clinical Oncology 2003-08-01

A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer.

Randolph S Marks, David L Graham, Jeff A Sloan, Shauna Hillman, Steven Fishkoff, James E Krook, Scott H Okuno, James A Mailliard, Tom R Fitch, Ferdinand Addo

Index: Am. J. Clin. Oncol. 26(4) , 336-7, (2003)

Full Text: HTML

Abstract

A phase II study of the dolastatin 15 analog LU 103793 was conducted by the North Central Cancer Treatment Group in patients with advanced non-small-cell lung cancer (SCLC). Previously untreated patients received this agent at a dosage of 2.5 mg/m2 as a 5-minute intravenous infusion for 5 consecutive days every 3 weeks. Between September 1997 and July 1998, 17 patients were accrued in this study. Forty-two treatment cycles were administered with relatively modest toxicity. No responses were seen. This agent appears to be inactive in the treatment of advanced non-SCLC.

Related Compounds

  • Dolastatin 15

Related Articles:

End-binding proteins sensitize microtubules to the action of microtubule-targeting agents.

2013-05-28

[Proc. Natl. Acad. Sci. U. S. A. 110(22) , 8900-5, (2013)]

The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma.

1995-06-01

[Anticancer Drugs 6(3) , 392-7, (1995)]

Effects of dolastatins on human B-lymphocytic leukemia cell lines.

1993-04-01

[Leuk. Res. 17(4) , 333-9, (1993)]

Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.

2012-09-01

[Cancer Chemother. Pharmacol. 70(3) , 439-49, (2012)]

Quantitation of dolastatin-10 using HPLC/electrospray ionization mass spectrometry: application in a phase I clinical trial.

1998-01-01

[Cancer Chemother. Pharmacol. 41(4) , 299-306, (1998)]

More Articles...